The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL)

Elena Maiolo; Eleonora Alma; Cecilia Napodano; Francesca Gulli; Silvia Bellesi; Annarosa Cuccaro; Krizia Pocino; Francesco D'Alo'; Marco Iachini; Maurizio Martini; Luigi Maria Larocca; Valerio De Stefano; Umberto Basile; Stefan Hohaus

doi:10.1080/10428194.2019.1706731

The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL)

Elena Maiolo, Eleonora Alma, Cecilia Napodano, Francesca Gulli, Silvia Bellesi, Annarosa Cuccaro, Krizia Pocino, Francesco D'Alo', Marco Iachini, Maurizio Martini, Luigi Maria Larocca, Valerio De Stefano, Umberto Basile, Stefan Hohaus

IRCCS Fondazione Policlinico Universitario A. Gemelli

Research output: Contribution to journal › Article › peer-review

Abstract

We analyzed the prognostic impact of levels of free light chains (FLC) in 106 patients with DLBCL, selecting 61 patients with a monoclonal (M) protein in serum, and 45 patients without a M protein as an IPI-matched control group. Patients with a M protein had higher levels of FLC, but these were not of prognostic significance in this group. The presence of a M protein nullified associations of κ-FLC with several laboratory parameters indicating immune system activation observed in patients without a M protein. Patients without M protein and κ-FLC >50 mg/L had a significant inferior event-free survival (p = .004). The presence of M protein of an IgM type at diagnosis was a negative outcome predictor (p = .008), while a non-IgM M protein did not significantly impact on prognosis. In conclusion, the prognostic performance of the FLC assay is altered by the presence of a M protein.

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.1080/10428194.2019.1706731
Publication status	E-pub ahead of print - Dec 31 2019

Access to Document

10.1080/10428194.2019.1706731

Cite this

Maiolo, E., Alma, E., Napodano, C., Gulli, F., Bellesi, S., Cuccaro, A., Pocino, K., D'Alo', F., Iachini, M., Martini, M., Larocca, L. M., De Stefano, V., Basile, U., & Hohaus, S. (2019). The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). Leukemia and Lymphoma, 1-7. https://doi.org/10.1080/10428194.2019.1706731

Maiolo, E, Alma, E, Napodano, C, Gulli, F, Bellesi, S, Cuccaro, A, Pocino, K, D'Alo', F, Iachini, M, Martini, M , Larocca, LM , De Stefano, V , Basile, U & Hohaus, S 2019, 'The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL)', Leukemia and Lymphoma, pp. 1-7. https://doi.org/10.1080/10428194.2019.1706731

@article{3559f09057de43f68887b0b8bf5b13d9,

title = "The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL)",

abstract = "We analyzed the prognostic impact of levels of free light chains (FLC) in 106 patients with DLBCL, selecting 61 patients with a monoclonal (M) protein in serum, and 45 patients without a M protein as an IPI-matched control group. Patients with a M protein had higher levels of FLC, but these were not of prognostic significance in this group. The presence of a M protein nullified associations of κ-FLC with several laboratory parameters indicating immune system activation observed in patients without a M protein. Patients without M protein and κ-FLC >50 mg/L had a significant inferior event-free survival (p = .004). The presence of M protein of an IgM type at diagnosis was a negative outcome predictor (p = .008), while a non-IgM M protein did not significantly impact on prognosis. In conclusion, the prognostic performance of the FLC assay is altered by the presence of a M protein.",

author = "Elena Maiolo and Eleonora Alma and Cecilia Napodano and Francesca Gulli and Silvia Bellesi and Annarosa Cuccaro and Krizia Pocino and Francesco D'Alo' and Marco Iachini and Maurizio Martini and Larocca, {Luigi Maria} and {De Stefano}, Valerio and Umberto Basile and Stefan Hohaus",

year = "2019",

month = dec,

day = "31",

doi = "10.1080/10428194.2019.1706731",

language = "English",

pages = "1--7",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL)

AU - Maiolo, Elena

AU - Alma, Eleonora

AU - Napodano, Cecilia

AU - Gulli, Francesca

AU - Bellesi, Silvia

AU - Cuccaro, Annarosa

AU - Pocino, Krizia

AU - D'Alo', Francesco

AU - Iachini, Marco

AU - Martini, Maurizio

AU - Larocca, Luigi Maria

AU - De Stefano, Valerio

AU - Basile, Umberto

AU - Hohaus, Stefan

PY - 2019/12/31

Y1 - 2019/12/31

N2 - We analyzed the prognostic impact of levels of free light chains (FLC) in 106 patients with DLBCL, selecting 61 patients with a monoclonal (M) protein in serum, and 45 patients without a M protein as an IPI-matched control group. Patients with a M protein had higher levels of FLC, but these were not of prognostic significance in this group. The presence of a M protein nullified associations of κ-FLC with several laboratory parameters indicating immune system activation observed in patients without a M protein. Patients without M protein and κ-FLC >50 mg/L had a significant inferior event-free survival (p = .004). The presence of M protein of an IgM type at diagnosis was a negative outcome predictor (p = .008), while a non-IgM M protein did not significantly impact on prognosis. In conclusion, the prognostic performance of the FLC assay is altered by the presence of a M protein.

AB - We analyzed the prognostic impact of levels of free light chains (FLC) in 106 patients with DLBCL, selecting 61 patients with a monoclonal (M) protein in serum, and 45 patients without a M protein as an IPI-matched control group. Patients with a M protein had higher levels of FLC, but these were not of prognostic significance in this group. The presence of a M protein nullified associations of κ-FLC with several laboratory parameters indicating immune system activation observed in patients without a M protein. Patients without M protein and κ-FLC >50 mg/L had a significant inferior event-free survival (p = .004). The presence of M protein of an IgM type at diagnosis was a negative outcome predictor (p = .008), while a non-IgM M protein did not significantly impact on prognosis. In conclusion, the prognostic performance of the FLC assay is altered by the presence of a M protein.

U2 - 10.1080/10428194.2019.1706731

DO - 10.1080/10428194.2019.1706731

M3 - Article

C2 - 31889454

SP - 1

EP - 7

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -

The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL)

Abstract

Access to Document

Fingerprint

Cite this